11th Asian Conference on Tumor Ablation (ACTA), October 25-27, 2025

Montpellier, September 4^th 2025– Quantum Surgical has obtained CE mark approval for the expanded use of its Epione® robotic platform in the treatment of bone tumors and metastases. The platform can also be used for bone consolidation. A third of cancer patients suffer from bone metastasis[1]. This new indication will be presented during the CIRSE congress, the largest interventional radiology event worldwide, held in Barcelona from September 13^th to15^th.

Quantum Surgical, acompany specializing in robotics and AI, develops the Epione^® robotic platform. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

 Epione allows physiciansto treat inoperable tumors that are particularly difficult to reach, due totheir size or their location, at an early stage, in a simple and effective way. 

 Epione® could until now be used to treat tumors in the abdomen (including the liver, kidneys, and pancreas) and the in the chest (lung). Over 1,000 patients have already been treated in Europe and the United States.  

Based on a clinical study conducted in three French hospitals - Gustave Roussy (Villejuif, the leading cancer center in Europe (4^th worldwide[2]), the Paoli-Calmettes Institute (Marseille) and the Hospices Civils de Lyon - the CE mark approval for bone tumors will expand this innovative, targeted, and minimally invasive treatment to new patients in Europe.

 Thanks to the new indication, Epione can also be used for other percutaneous procedures, such as bone consolidation (pelvis and spine). Bone consolidation can help reduce patients’ pain and improve their mobility[3].  

 “Given that a third of cancer patients suffer from bone metastasis and weaknesses, which can be very painful,the entire Quantum Surgical’s team is delighted to obtain the new CE mark. New patients in Europe will be able to benefit from our innovative technology and will therefore experience a more comfortable health care pathway” says Bertin Nahum, CEO and co-founder of Quantum Surgical.

"The clinical study conducted at Gustave Roussy has demonstrated the relevance of Epione in the practice of bone percutaneous procedures. We will keep integrating robotics in these procedures which allow for better patient care" explains Dr. Baptiste Bonnet, interventional radiologist at Gustave Roussy.

Laetitia Messner, Chief Clinical Officer at Quantum Surgical develops “Conducted by Dr. Bonnet, the clinical study has demonstrated the clinical performance and safety of Epione in the treatment of bone lesions and, more broadly, in the execution of percutaneous bone procedures, which until now had been performed manually. The expanded careoffering provided by Epione will support both physicians and patients throughout the therapeutic pathway”.

Epione is currentlyavailable in about fifteen hospitals in Europe and in the United States.  

Epione® device is CE marked for abdomen, chest and musculoskeletal structures indications, and FDA cleared for abdominal ablation indication.

About Quantum Surgical

QuantumSurgical is a company specializing in medical robotics company and artificial intelligence co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team ofover 130 employees, the company has offices in Montpellier, France, and Miami,Florida.

Its Epione^® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. More than 1,000patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program that supports top emerging actors in disruptive innovation.

Moreinformation: www.quantumsurgical.com

[1] Info Cancer

[2] Gustave Roussy, 2025

[3] Image-Guided Bone Consolidation in Oncology

‍

Discover the power of Robotics in Image Guided Ablation during our upcoming webinar, featuring a live Q&A. Get your questions answered by experts from around the world. Don't miss this insightful session brought to you by Spectrum Cancer and Quantum Surgical.

‍

Topics include:

• Benefits and challenges of robotics during ablation procedures
• Learning curves
• How to approach administration about adopting robotics
• Case presentations
• And live Q&A

Join us for this virtual event with live Q&A.

Limited spots. 

REGISTER NOW!

Organized by the Cardiovascular and Interventional Radiology Society of Europe, the CIRSE 2025 event is the world's biggest meeting focusing on interventional radiology and will take place in Barcelona, Spain from September 13-17, 2025.

For 40 years, the CIRSE annual congress has provided the world’s premier platform for specialists in minimally invasive image-guided procedures to meet, share and connect. Quantum Surgical is delighted to announce its renewed participation this year, underscoring our commitment to advancing medical innovation and collaboration within this dynamic community.

Explore Epione^®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.

‍

Don’t miss the opportunity to learn more about the Epione^®, a unique robotic-assisted platform, at the ECIO:

• e-POSTER P-0134

Feasibility, safety and accuracy of robotic-assisted CT-guided percutaneous ablation in bone - EPIBONE

Dr. Baptiste Bonnet - Gustave Roussy (Villejuif, France)

CHECK e-POSTER

• e-POSTER P-0767

Robotic assistance for irreversible electroporation: meeting the needle placement pattern requirements with none to minimal adjustments 

Prof. Laurent Milot - Hôpital Edouard Herriot, Hospices Civils de Lyon (Lyon, France)

CHECK e-POSTER

• e-POSTER P-1113

Safety and Accuracy of Robotic Assisted Microwave Ablation: First American Experience on 98 patients

Dr. Susan Van Der Lei - Amsterdam UMC (Amsterdam, Netherlands), Baptist Health (Miami, USA)

CHECK e-POSTER

‍

Event Details:

• Date: September 13-17, 2025
• Location: Centre de Convencions International de Barcelona, Spain

‍